TMCnet News

Research and Markets: Pollen Allergy Pipeline Review, H2 2015
[November 27, 2015]

Research and Markets: Pollen Allergy Pipeline Review, H2 2015


Research and Markets (http://www.researchandmarkets.com/research/7hkjfn/pollen_allergy) has announced the addition of the "Pollen Allergy - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeuic development for Pollen Allergy and special features on late-stage and discontinued projects.



The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development


  • ALK-Abello A/S
  • Allergopharma Joachim Ganzer KG
  • Allergy Therapeutics Plc
  • Anergis SA
  • Biomay AG
  • BioTech Tools s.a.
  • Circassia Pharmaceuticals Plc
  • HAL Allergy BV
  • Immunomic Therapeutics, Inc.
  • Japan Tobacco Inc.
  • Laboratorios LETI S.L.
  • REGiMMUNE Corporation
  • Roxall Medizin GmbH
  • Shionogi & Co., Ltd.
  • Stallergenes S.A.

For more information visit http://www.researchandmarkets.com/research/7hkjfn/pollen_allergy


[ Back To TMCnet.com's Homepage ]